New Blood Test Linked to the Likelihood of Anaphylaxis from Peanut Allergy

Medical/Healthcare News© Jae Young Ju / Getty Images / Canva

PHILADELPHIA, PA — AllerGenis announced a third presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2023, which occurred on June 11th in Hamburg, Germany.

The presentation entitled, “Severity Stratification of Peanut Allergic Subjects Using Epitope Mapping”, demonstrated that a non-invasive blood test (ses-IgE) is able to predict the Cumulative Reactive Dose (CRD), or how much peanut ingested causes a reaction during a peanut Oral Food Challenge, as well as the severity of symptoms likely to be experienced at that CRD (amount of peanut).

The research was conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, in New York, Mahidol University in Bangkok, Thailand, and the Imperial College of London in the United Kingdom. The study found that the new blood test demonstrated a high degree of stratification between patient groups who are likely to experience anaphylaxis, a severe food allergy reaction, and has the potential to impact upon a decision to proceed to food challenge as well as identifying those who might benefit from immunotherapy.

Presenting the findings was Doctor Paul Turner, Clinician Scientist and Honorary Consultant in Paediatric Allergy & Immunology at Imperial College London. Turner said, “Existing tests for food allergy do not reliably predict how much someone might react to, or how bad a reaction they may have. The Bead-Based Epitope Assay has already been shown to give better information on the former, i.e., how sensitive a person with food allergy is. These new data show that the assay can also provide valuable information as to the likelihood of a more severe reaction, called anaphylaxis.” Turner added, “This would represent a paradigm-shift in the information which can be provided by a non-invasive test.”

READ:  Mamajuana Café to Spice Up Philadelphia with Its First Location

“Our pioneering research at AllerGenis is aimed at enhancing patient outcomes and reducing undue risks. The information gained from our innovative blood test can critically shape the decision-making process around food challenges and the identification of patients who could see benefits from immunotherapy. This is a remarkable stride forward in the field of personalized medicine for food allergies”, said Thomas Vollmers, Head of Strategic Partnerships with AllerGenis, an expert in Companion Diagnostics.

Jim Garner, CEO of AllerGenis, said this, “We are passionate about helping people get clarity around their diagnosis, management, and treatment of their food allergies, helping to improve their quality of life, by feeling safe, in control, and confident when and where they eat.

Food allergies exact a toll on individuals and families. Significant out of pocket expense, as well as a great deal of anxiety which drives a wholesale change of lifestyle. For the parents, anxiety mounts and stress and worry become an all-day issue – every snack, every meal, eating at school, attending birthday parties, sleep overs, camp. Parents and caregivers, especially moms, make a huge number of accommodations to their own personal lives to ensure their children remain safe when eating. We are excited to continue our effort in developing better tools, using cutting-edge systems biology and data analytics enabling precision diagnostic solutions to accurately determine allergic status and thoroughly address clinical questions,” Garner added.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.